<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012141</url>
  </required_header>
  <id_info>
    <org_study_id>AU 793</org_study_id>
    <nct_id>NCT01012141</nct_id>
  </id_info>
  <brief_title>Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer</brief_title>
  <acronym>PROTAXY</acronym>
  <official_title>Pilot Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First Line Treatment of Hormone Independent Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE : Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
      growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary
      supplements, such as phytochemicals, may stop or delay the development of prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the pathological response rate in metastatic prostate
      cancer patients treated by : Docetaxel with a phytochemical
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as assessed by clinical, biological and paraclinical examination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the best neuroendocine markers between chromogranin A (CgA), neuron-specific enolase (NSE) and serotonin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as assessed by RECIST criteria and PSA level</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess compliance of per os phytonutrient treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment impact on compliance</measure>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>phytochemical</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18

          -  WHO performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Patients receiving androgen-suppressive therapy in the form of chirurgical castration
             by orchiectomy or pulpectomy,or medical by LHRH agonist or antagonist with or without
             anti-androgen or all treatment blocking non gonadic testosterone fraction

          -  Resulting to testosteronemia &lt;0,5 ng/ml

          -  Histologically confirmed adenocarcinomia of prostate cancer and documented hormone
             independant metastatic disease - defined by: objective progression with at least one
             measurable lesion and/or evaluable lesion according to RECIST criteria and /or a rise
             in PSA level (&quot;rising PSA&quot;)

          -  Total bilirubin ≤ upper limit of normal (ULN).

          -  AST and ALT ≤ 1.5 times ULN. Alkaline phosphatase ≤ 2.5 times ULN.

          -  Serum creatinine &lt; 140 µmol/L or creatinine clearance &gt; 60 mL/ min.

          -  Neutrophil count &gt; 2.109 L-1.

          -  Platelet count ≥ 100,000/mm3.

          -  Hemoglobin ≥ 10 g/dL

          -  Not previous chemotherapy, except Estracyt

          -  No liver, kidney or heart failure link to treatment

          -  No malabsorption syndrome or disease significantly affecting gastrointestinal function

          -  Prior radiotherapies are permetted withing four weeks of the first study treatment and
             must be &lt; 25 % of the bone marrow, and all adverse events must be resolved

          -  Prior surgery are permitted.

        Exclusion Criteria:

          -  Age &lt; 18

          -  History of psychiatric disorders including psychotic disorder, dementia or seizures
             that would prohibit the understanding, observance and giving of informed consent

          -  Previous or concomitant other malignancies except basal or squamous cell carcinoma of
             the skin or other cancer curatively treated with surgery and/or radiotherapy

          -  Patients should not have symptomatic brain metastasis

          -  Concurrent severe and/or uncontrolled co-morbid medical condition

          -  Malabsorption syndrome or disease significantly affecting gastro-intestinal function
             or major resection of the stomach, proximal small bowel or grade &gt; 2 dysphagia

          -  Patients with uncontrolled infection

          -  History of significant neurologic (i.e. peripheral neuropathy grade &gt; 2 using NCI-CTC
             criteria v3.0)

          -  Patients should not have received NSAIDs or COX2 inhibitors within the three weeks
             prior to starting the study

          -  Treatment with any investigational drug within 30 days prior to registration

          -  Patients should not have current regimen containing dietary phytonutrients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Chollet, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Jean Perrin</investigator_affiliation>
    <investigator_full_name>Philippe Chollet</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

